慧聚药业总裁邹平：“从原料药到制剂，这条路，我们打通了”

Core Viewpoint - Jiangsu Huiju Pharmaceutical Co., Ltd. has successfully transitioned from raw materials to high-end formulations, with its first oral sustained-release formulation, Fenobert Choline, recently approved by the National Medical Products Administration, marking a significant milestone for the company [1][2]. Group 1: Company Development - The company was founded in 2000 and has over 160 raw materials in production, serving more than 300 global clients [2]. - The company has invested over 1 billion yuan in a high-end formulation R&D, transformation, and manufacturing integrated platform project, which is currently under construction [2][3]. - The first formulation product, Acetylcysteine Injection, was approved for market entry in December 2024, and it won supply rights in six provinces in China [3][4]. Group 2: Strategic Focus - The company aims to build a complete industrial chain by integrating R&D, transformation, production, and sales, aligning with modern pharmaceutical industry trends towards automation and efficiency [3][4]. - The company is focusing on high-tech areas with significant potential, such as oral dissolving films, fully isolated anti-cancer drug formulations, freeze-dried tablets, and capsules [4]. Group 3: Talent and Innovation - The company faces challenges in transitioning from raw materials to formulations, including high technical barriers and a shortage of professional talent [5]. - The company has implemented attractive talent recruitment and incentive policies to create a conducive environment for talent retention and development [5][6]. - The company has increased its R&D efforts in innovative drugs, addressing critical issues in the domestic biopharmaceutical sector and promoting localization and cost reduction [6].